Analysis Date: 2026-02-24T13:57:47.988334 Trading Period: 2025-12-25 to 2026-01-08
Company: Novo Nordisk A/S Sector: Healthcare | Industry: Drug Manufacturers - General Current Price: $39.63 Market Cap: $176,223,404,032 Beta: 0.40 Avg Volume: 21,359,528 P/E Ratio: 10.86 Website: https://www.novonordisk.com
Description: Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The c...
Action: STRONG AVOID Confidence: 20.0/100 Position Size: 0.0% of portfolio
Rationale: Unfavorable conditions (composite: 11.8/100, risk: EXTREME, red flags: 5).
Key Risks:
Passed Filters: ✗ No Notes: Failed one or more screening filters (volume, price, market cap, etc.)
Composite Score: 0.00/5.0 Percentile Rank: 0%
Factor Scores:
Setup Score: 2/8 Setup Notes: High volume today (3.8x)
Price Levels:
Momentum & Volume:
Risk Level: EXTREME Confidence: 10.0/100 Total Red Flags: 5 Earnings Risk: No
Critical Issues:
Market Red Flags:
Stock-Specific Red Flags:
This report is generated by PM automated research system. Always perform your own due diligence before trading.